Gemcitabine-induced radiation recall in the treatment of pancreatic cancer

Asia-Pacific Journal of Clinical Oncology

Volumn 5, Issue 1, 2009, Pages 17-23

  Wan Zainon, Wan Mohd Nazri ^a   Borg, M ^b   Higgs, B ^a   Yeoh, E ^a   Kotasek, D ^c   Parnis, F ^c   Hillenband, E ^c   Hamzah, S ^d  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b Adelaide Radiotherapy Centre   (Australia)

^c Adelaide Cancer Centre   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Carcinoma; Gemcitabine; Pancreas; Radiation recall

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; FLUOROURACIL; GEMCITABINE; OMEPRAZOLE; PREDNISOLONE; SCOPOLAMINE BUTYL BROMIDE;

ABDOMINAL WALL MUSCULATURE; ADULT; ARTICLE; BRAIN STEM INJURY; CANCER LOCALIZATION; CASE REPORT; CHEMOTHERAPY INDUCED EMESIS; COHORT ANALYSIS; CONSTIPATION; CONTINUOUS INFUSION; DEHYDRATION; DERMATITIS; DIARRHEA; DIGESTIVE SYSTEM INFLAMMATION; DRUG WITHDRAWAL; EPIGASTRIC PAIN; GASTROINTESTINAL HEMORRHAGE; HUMAN; LYMPHANGITIS; MALE; MEDICAL RECORD; MEDLINE; MULTIPLE CYCLE TREATMENT; MYOSITIS; NAUSEA; OPTIC NERVE DISEASE; OPTIC NEURITIS; PANCREAS CANCER; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN INFLAMMATION; TREATMENT OUTCOME;

EID: 61649093081     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2009.01187.x     Document Type: Article

References (40)

1. Friedlander PA, Bansal R, Schwartz L, Wagman R, Posner J, Kemeny N. Gemcitabine-related radiation recall preferentially involves internal tissue and organs. Cancer 2004; 100: 1793-9.
2. Pauwels B, Korst AEC, Lardon F, Vermorken JB. Combined modality therapy of gemcitabine and radiation. Oncologist 2005; 10: 34-51.
3. Castellano D, Hitt R, Cortes-Funes H et al. Radiation recall induced by gemcitabine. J Clin Oncol 2000; 18: 695-6.
4. Burstein H. Radiation recall dermatitis from gemcitabine. J Clin Oncol 2000; 18: 693-4.
5. Bar-Sela G, Beny A, Bergman R, Kutan A. Gemcitabine-induced radiation recall dermatitis: Case report. Tumori 2001; 87: 428-30.
6. Jeter M, Pasi J, Brooks S et al. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys 2002; 53: 394-400.
7. Schwartz BM, Khuntia D, Kennedy AW, Markman M. Gemcitabine-induced radiation recall dermatitis following whole pelvic radiation therapy. Gynaecol Oncol 2003; 91: 421-2.
8. Welsh JS, Torre TG, DeWeese TL, O'Reilly SO. Radiation myositis. Ann Oncol 1999; 10: 1105-8.
9. Ganem G, Solal-Celigny P, Joffroy A et al. Radiation myositis: The possible role of gemcitabine. Ann Oncol 2000; 11: 1615-16.
10. Fogarty G, Ball D, Rischin D. Radiation recall reaction following gemcitabine. Lung Cancer 2001; 33: 299-302.
11. Fakih MG. Gemcitabine-induced rectus abdominus radiation recall. JOP 2006; 7: 306-10.
12. Saif MW et al. Gemcitabine-related radiation recall in a patient with pancreatic cancer. Anti-Cancer Drugs 2006; 17: 107-11.
13. Willett CG et al. Clinical research in pancreatic cancer: The radiation therapy oncology group trials. Int J Radiat Oncol Biol Phys 2003; 54: 31-7.
14. Anderson H, Hopwood P, Stephens RJ et al. Gemcitabine plus best supportive care (BSC) vs. BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Br J Cancer 2000; 83: 447-53.
15. Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15: 2403-13.
16. Lorusso V, Pollera CF, Antimi M et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 1998; 34: 1208-12.
17. Spielmann M, Llombart Cussac A, Kalla S et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 2001; 60: 303-7.
18. Lund B, Hansen OP, Neij JP et al. Phase II study of gemcitabine (2′, 2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86: 1530-3.
19. Einhorn LH, Stender MJ, Williams SD. Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol 1999; 17: 509-11.
20. Cormier Y, Eisenhauer E, Muldal A et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1994; 5: 283-5.
21. Kubicka S, Rudolph KL, Tietze MK et al. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 2001; 48: 783-9.
22. Catimel G, Vermorken JB, Clavel M et al. A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994; 5: 543-7.
23. Mutch DG, Bloss JD. Gemcitabine in cervical cancer. Gynecol Oncol 2003; 90: S8-S15.
24. Dumontet C, Morschhauser F, Solal-Celigny P et al. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br J Haematol 2001; 113: 772-8.
25. Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 2001; 113: 185-7.
26. Heinemann V, Hertel LW, Grindey GB et al. Comparison of the cellular pharmacokinetics and toxicity of 2′, 2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 1988; 48: 4024-31.
27. Huang P, Chubb S, Hertel LW et al. Action of 2′, 2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51: 6110-17.
28. Ruiz van Haperen VW, Veerman G, Vermorken JB et al. 2′, 2′-difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol 1993; 46: 762-6.
29. Tolis C, Peters GJ, Ferreira CG et al. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer 1999; 35: 796-807.
30. Pauwels B, Korst AEC, Pattyn GGO et al. Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro. Int J Radiat Oncol Biol Phys 2003; 57: 1075-83.
31. Bouffard DY, Momparler RL. Comparison of the induction of apoptosis in human leukemic cell lines by 2′, 2′-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside. Leuk Res 1995; 19: 849-56.
32. Huang P, Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 1995; 36: 181-8.
33. Ferreira CG, Tolis C, Span SW et al. Drug-induced apoptosis in lung cancer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway. Clin Cancer Res 2000; 6: 203-12.
34. Bostrom A, Sjolin-Forsberg G, Wilking N, Bergh J. Radiation recall: another call with tamoxifen. Acta Oncol 1999; 38: 955-9.
35. Hellman S, Botnick LE. Stem cell depletion: An explanation of the late effects of cytotoxins. Int J Radiat Oncol Biol Phys 1977; 2: 181-4.
36. Seymour CB, Mothersill C, Alper T. High yields of lethal mutations in somatic mammalian cells that survive ionizing radiation. Int J Radiat Oncol Biol Phys 1986; 50: 167-79.
37. Kitani H, Kosaka T, Fujihara T, Lindquist K, Elkind MM. The recall effect in radiotherapy: Is subeffective, reparable damage involved? Int J Radiat Oncol Biol Phys 1990; 18: 689-95.
38. Abadir R, Liebmann J. Radiation recall following simvastatin therapy: A new observation. Clin Oncol 1995; 7: 325-6.
39. Wintroub BU, Stern R. Cutaneous drug reactions: Pathogenesis and clinical classification. J Am Acad Dermatol 1985; 13: 167-9.
40. Hall EJ. Clinical response in normal tissues. In: Hall EJ, Giaccia AJ. (eds). Radiobiology for the Radiologist, 5th edn. Lippincott Williams and Wilkins, Philadelphia 2000; 339-60.